Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention

Coron Artery Dis. 2016 Nov;27(7):580-5. doi: 10.1097/MCA.0000000000000394.

Abstract

Introduction: Primary percutaneous coronary intervention (PCI) is the preferred method of reperfusion in ST-segment elevation myocardial infarction patients. Adjunctive pharmacotherapy is, however, still under investigation.

Objective: To assess the effect of combined pharmacologic therapy on myocardial perfusion and infarct size in relation to time delays.

Materials and methods: We studied 309 consecutive ST-segment elevation myocardial infarction patients admitted within 12 h from symptom onset with (a) chest pain persisting for more than 30 min, (b) ST-segment elevation more than 1 mm in at least two contiguous leads, and (c) pretreatment with 600 mg of clopidogrel, 300 mg of aspirin, and 5000 U of intravenous heparin. Group I (n=90) included patients transferred directly to cathlab (immediate transfer) and group II (n=219) included patients transferred by referring hospitals (staged transfer). The results of thrombolysis in myocardial infarction (TIMI) flow before and after PCI, ST-segment resolution (STSR), troponin T level, and myocardial blush grade were analyzed in relation to delay to intervention.

Results: The delay between pharmacologic pretreatment and angiography was two times longer in cases of staged transfer (80 vs. 47.5 min; P<0.0001). Despite the longer delay, higher rates of preangiography total STSR (26.4 vs. 15.5%; P=0.039) and initial TIMI flow 3 (20.1 vs. 11.1%; P=0.059) were observed in those patients. Differences in the rate of total STSR (70.3 vs. 66.7%; P=0.52), TIMI flow 3 (91.3 vs. 88.9%; P=0.33), and myocardial blush grade (60.7 vs. 63.3%; P=0.66) were no longer observed after PCI. Similarly, the peak troponin T level was also comparable (3.6 vs. 3.9 ng/ml; P=0.74).

Conclusion: Pretreatment with a combination of antiplatelet and antithrombotic agents may improve myocardial perfusion and compromise longer delay to a mechanical intervention.

Publication types

  • Comparative Study
  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aspirin / administration & dosage*
  • Aspirin / adverse effects
  • Biomarkers / blood
  • Clopidogrel
  • Coronary Angiography
  • Coronary Circulation / drug effects*
  • Drug Therapy, Combination
  • Electrocardiography
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Heparin / administration & dosage*
  • Heparin / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Patient Transfer
  • Percutaneous Coronary Intervention* / adverse effects
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Prospective Studies
  • ST Elevation Myocardial Infarction / blood
  • ST Elevation Myocardial Infarction / diagnostic imaging
  • ST Elevation Myocardial Infarction / physiopathology
  • ST Elevation Myocardial Infarction / therapy*
  • Ticlopidine / administration & dosage
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Time Factors
  • Time-to-Treatment
  • Treatment Outcome
  • Troponin T / blood

Substances

  • Biomarkers
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Troponin T
  • Heparin
  • Clopidogrel
  • Ticlopidine
  • Aspirin